| Literature DB >> 35604474 |
Jack Rychik1,2,3, David J Goldberg4,5, Elizabeth Rand6,5, Edna E Mancilla7,5, Jennifer Heimall8,5, Nicholas Seivert9,10, Danielle Campbell11, Shannon O'Malley4, Kathryn M Dodds4,12,13.
Abstract
Today, it is anticipated most individuals diagnosed with single-ventricle malformation will survive surgical reconstruction through a successful Fontan operation. As greater numbers of patients survive, so has the recognition that individuals with Fontan circulation face a variety of challenges. The goal of a normal quality and duration of life will not be reached by all. The hurdles fall into a variety of domains. From a cardiovascular perspective, the Fontan circulation is fundamentally flawed by its inherent nature of creating a state of chronically elevated venous pressure and congestion, accompanied by a relatively low cardiac output. Ventricular dysfunction, atrioventricular valve regurgitation, and arrhythmia may directly impact cardiac performance and can progress with time. Problems are not limited to the cardiovascular system. Fontan circulatory physiology impacts a multitude of biological processes and health parameters outside the heart. The lymphatic circulation is under strain manifesting as variable degrees of protein-rich lymph loss and immune system dysregulation. Organ system dysfunction develops through altered perfusion profiles. Liver fibrosis is ubiquitous, and a process of systemic fibrogenesis in response to circulatory stressors may affect other organs as well. Somatic growth and development can be delayed. Behavioral and mental health problems are common, presenting as clinically important levels of anxiety and depression. Most striking is the high variability in prevalence and magnitude of these complications within the population, indicating the likelihood of additional factors enhancing or mitigating their emergence. We propose that optimal care for the individual with single ventricle and a Fontan circulation is ideally offered in a comprehensive multidisciplinary manner, with attention to elements that are beyond cardiac management alone. In this report, we share the concepts, our experiences, and perspectives on development of a clinic model-the "Fontan rehabilitation, wellness and resilience development" or FORWARD program. We provide insights into the mechanics of our multidisciplinary model of care and the benefits offered serving our growing population of individuals with a Fontan circulation and their families.Entities:
Keywords: Fontan circulation; Fontan-associated liver disease; Multidisciplinary care; Single ventricle
Mesh:
Year: 2022 PMID: 35604474 PMCID: PMC9125546 DOI: 10.1007/s00246-022-02930-z
Source DB: PubMed Journal: Pediatr Cardiol ISSN: 0172-0643 Impact factor: 1.838
Fig. 1The heart–liver interaction in the patient with single ventricle and potential factors influencing the development of “Fontan-associated liver disease”
Fig. 2Liver biopsy samples with Sirius red staining for quantification of percent collagen deposition. Utilizing this technique allows for quantification of a global burden of fibrosis per area of tissue analyzed. Case 1 with a minimal amount of fibrosis, and cases 2 and 3 with more significant amounts of fibrosis
Fig. 3Growth charts of male patient with Fontan physiology, complicated by PLE at age 9y, treated with diuretics and steroids (oral controlled release budesonide) with subsequent growth failure and delayed puberty. Growth charts show catch-up growth with a delayed pubertal growth spurt after resolution of PLE, budesonide wean and improved nutritional intake. a Height for age curve, b weight for age curve
Fig. 4Eight year old with Fontan circulation and extensive molluscum contagiosum on both arms
Evaluations offered at the FORWARD clinic multidisciplinary evaluation. Multidisciplinary evaluations are suggested following Fontan operation, every 3 years in childhood and every 2 years in adolescence
| Clinical domain | Testing | Frequency of surveillance? |
|---|---|---|
| Blood Laboratories | Complete blood count with differential | At each visit |
| Comprehensive metabolic panel (includes electrolytes, BUN and creatinine, calcium, liver function tests, total protein, albumin) | At each visit | |
| Cystatin C | At each visit | |
| Gamma-glutamyl transferase | At each visit | |
| Parathyroid hormone | At each visit | |
| 25 OH Vitamin D | At each visit | |
| Brain natriuretic peptide | At each visit | |
| IgG Immunoglobulin | At each visit | |
| Alpha feto-protein | When imaging reveals suspicious hepatic structure and routinely in adolescence | |
| Stool alpha-1-antitrypsin level | When there is low serum albumin levels; suspicion of, or monitoring for PLE | |
| Cardiovascular | Electrocardiogram | At each visit |
| Echocardiogram | At each visit | |
| Holter monitoring | At each visit | |
| Exercise stress test | At each visit. Without metabolic assessment starting at approximately age 7, with metabolic assessment approximately age > 9 years | |
| Six-minute walk test | At each visit for young patients and for those unable to do full exercise test with metabolic assessment | |
| Cardiac MRI | As indicated based on clinical needs, and routinely performed every 2-–3 years when achievable without sedation (typically > age 11 years) | |
| CT angiography | As indicated based on clinical needs and when MRI not feasible | |
| Liver | Abdominal ultrasound imaging with Doppler | At each visit |
| Ultrasound elastography | At each visit (ultrasound is our standard choice) | |
| MRI elastography (no contrast) | At each visit, in those who have had prior MRI elastography for consistency in serial evaluation | |
| MRI imaging with gadolinium-based contrast | In the presence of suspicious lesions on ultrasound | |
| Immunology | Flow cytometry-based enumeration of T-, B-, and NK-cells | In those with absolute lymphocyte counts < 1000 cells/microliter |
| Endocrinology | Dual X-ray Absorptiometry Scan (DXA) | At each visit |
| 8 AM Cortisol level | Patients with PLE on steroid therapy | |
| Bone age X-ray | Only as clinically indicated, growth concerns | |
| Thyroid studies (Thyroid stimulating hormone, free T4) | Only as clinically indicated, growth concerns and in those with PLE | |
| Insulin-like growth factor 1 and Insulin-like growth factor binding protein 3 | Only as clinically indicated, growth concerns | |
| Nutrition | 24-h dietary recall | At each visit |
| Computerized dietary analysis of 3-day food record | When clinically indicated, growth concerns | |
| Behavioral Health/Psychology | Behavioral assessment scale for children [BASC-3], Parent, and Self-Report | At each visit |
| Pediatric Cardiac Quality of Life Inventory [PCQLI]), Parent and Self-Report | At each visit | |
| PROMIS Global Health/Quality of Life | At each visit | |
| Brief Pediatric Inventory for Parents (measure of parental distress related to child’s medical condition) | At each visit |
Fig. 5The medication distribution in a sample of 343 patients seen in FORWARD clinic. ACEI, angiotensin converting enzyme inhibition; ALDOST aldosterone; PDE5I phosphodiesterase—5—enzyme inhibition. Note 10% of our population in this sample are on psychiatric or behavior modifying medications
Fig. 6The absolute lymphocyte count (cells per microliter) distribution based on age at evaluation in a sample of 319 patients evaluated in FORWARD clinic. Normal value for lower limit of absolute lymphocyte count in our laboratory is 1160 cells/microliter. The curve is significant at p value < 0.01
Fig. 7The platelet count (10*3 per microliter) distribution based on age at evaluation in a sample of 325 patients evaluated in FORWARD clinic. The curve is significant at p value < 0.01
Fig. 8The serum gamma glutamyl transferase (U per liter) distribution based on age at evaluation in a sample of 282 patients evaluated in FORWARD clinic. Upper limit of normal in our laboratory is 21 u/L. The curve is significant at p value < 0.01